Healthcare | April 29, 2026
Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Rs. 40 cr buyback, 200% dividend announced
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
